Skip to main content
Log in

The effect of colchicine and disease severity on physical growth in children with familial Mediterranean fever

Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study aimed to investigate the effects of colchicine on growth parameters in familial Mediterranean fever (FMF) patients. Fifty-one (29 girls, 22 boys) FMF patients were enrolled in the study. All of the patients were in the prepubertal stage and had not received colchicine treatment before the study. Anthropometric measurements, demographic features, clinical findings at diagnosis and during periods of attacks of FMF, disease activity, frequency of exacerbations, colchicine dosage, and weight and height measurements were recorded at an interval of 6 months. Height, weight, and body mass index standard deviation scores and Z-scores were calculated. The mean height standard deviation score (HSDS) was significantly increased from −0.64 ± 1.20 to −0.26 ± 1.07 (p < 0.001), the mean weight standard deviation score (WSDS) was significantly increased from −0.60 ± 1.03 to −0.45 ± 0.98 (p = 0.008), and the mean body mass index standard deviation score was decreased from −0.33 ± 1.06 to −0.47 ± 0.98 (p = 0.128) at 1 year after colchicine treatment compared with before initiation of treatment. In patients who had no FMF attacks during colchicine treatment, height and weight were significantly increased at 1 year (HSDS: p < 0.001 WSDS: p = 0.002), but in patients who had recurrent attacks, height and weight did not change (HSDS: p = 0.051, WSDS: p = 0.816). Even when subclinical inflammation is present, preventing attacks of FMF with colchicine allows growth to continue. However, suppression of subclinical inflammation and control of attacks of FMF are required for weight gain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Gang N, Drenth JP, Langevitz P et al (1999) A. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 26:890–897

    CAS  PubMed  Google Scholar 

  2. De Benedetti F, Alonzi T, Moretta A et al (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin like growth factor-1: a model for stunted growth in children with chronic inflammation. J Clin Invest 99:643–650

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bakkaloğlu A (2003) Familial Mediterranean fever. Pediatr Nephrol 18:853–859

    Article  PubMed  Google Scholar 

  4. Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45:746–750

    Article  CAS  Google Scholar 

  5. Ozçakar B, Kadıoğlu G, Sıklar Z et al (2010) The effect of colchicine on physical growth in children with familial Mediterranean fever. Eur J Pediatr 169(7):825–828

    Article  PubMed  Google Scholar 

  6. Zung A, Barash G, Zadik Z, Barash J (2006) Familial Mediterranean fever and growth: effect of disease severity and colchicine treatment. J Pediatr Endocrinol Metab 19(2):155–160

    Article  PubMed  Google Scholar 

  7. Türkmen M, Soylu OB, Kasap B et al (2008) Growth in familial Mediterranean fever: effect of attack rate, genotype and colchicine treatment. J Pediatr Endocrinol Metab 21(8):789–792

    Article  PubMed  Google Scholar 

  8. Yalçınkaya F, Ozen S, Ozçakar B et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48:395–398

    Article  Google Scholar 

  9. Livneh A, Langevitz P, Zemer D et al (1996) The changing of familial Mediterranean fever. Semin Arthritis Rheum 26:612–627

    Article  CAS  PubMed  Google Scholar 

  10. Pras E, Livneh A, Balow JE Jr (1998) Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet 75:216–219

    Article  CAS  PubMed  Google Scholar 

  11. Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291–303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Marshall WA, Tanner JM (1970) Variations in pattern of pubertal changes in boys. Arch Dis Child 45:13–23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zemer D, Livneh A, Danon T et al (1991) Long term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977

    Article  CAS  PubMed  Google Scholar 

  14. Ben-Cherit E, Levy M (1991) Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 20:241–246

    Article  Google Scholar 

  15. Savgan-Gürol E, Kasapçopur Ö, Hatemi S et al (2001) Growht and IGF-1 levels of children with familial Mediterranean fever on colchicine treatment. Clin Exp Rheumatol 19(Suppl 24):72–75

    Google Scholar 

  16. Padeh S, Gerstein M, Berkun Y (2012) Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr 161:1142–1146

    Article  CAS  PubMed  Google Scholar 

  17. Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287:1302

    CAS  PubMed  Google Scholar 

  18. Goldfinger S (2009) The inherited autoinflammatory syndrome: a decade of discovery. Trans Am Clin Climatol Assoc 120:413–418

    PubMed  PubMed Central  Google Scholar 

  19. Ozkan E, Okur O, Ekmekci A et al (1972) A new approach to the treatment of periodic fever. Med Bull Istanbul 5:44–49

    Google Scholar 

  20. Zemer D, Revach M, Pras M et al (1974) A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 291:932–934

    Article  CAS  PubMed  Google Scholar 

  21. Başaran Ö, Uncu N, Çelikel BA et al (2014) Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 22:1–4

    Google Scholar 

  22. Meinzer U, Quartier P, Alexandra JF et al (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41:265–71

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

None.

Compliance with ethical standards

Ethics approval

The study was approved by the local hospital ethics committee and performed according to the Declaration of Helsinki and Good Clinical Practice guidelines.

Consent to participate

Written informed consent was obtained from every participant.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Banu Acar.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoldaş, T.Ç., Çakar, N., Başaran, Ö. et al. The effect of colchicine and disease severity on physical growth in children with familial Mediterranean fever. Clin Rheumatol 35, 1603–1607 (2016). https://doi.org/10.1007/s10067-015-3077-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-3077-9

Keywords

Navigation